Holen Sie sich die Stockscreener-App
11.20
2.38%
0.26
Handel nachbörslich:
11.23
0.03
+0.27%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RCEL?
Forum
Prognose
Aktiensplit
Avita Medical Inc Aktie (RCEL) Neueste Nachrichten
Precision Trading with Avita Medical Inc. (RCEL) Risk Zones - Stock Traders Daily
564,952 Shares in Avita Medical Inc. $RCEL Bought by BlackRock Inc. - MarketBeat
RCEL stock gains on fresh price data while Avita Medical readies next steps - AD HOC NEWS
Gross margin % of AVITA Medical Inc Shs Chess Depository Interests repr 0.2 shs – HAM:51KB - tradingview.com
AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference - Investing News Network
AVITA Medical to Showcase Leadership at Lake Street and Morgan Stanley Healthcare Conferences in September 2026 - Kalkine Media
AVITA Medical Inc Shs Chess Depository Interests repr 0.2 shs Balance Sheet – HAM:51KB - tradingview.com
51KB Stock Price and Chart — HAM:51KB - tradingview.com
All You Need to Know About Avita Medical (RCEL) Rating Upgrade to Buy - Yahoo Finance
Avita Medical Inc.ADR Peer Comparison – Compare with Others - Value Research
Lake Street Maintains Avita Medical(RCEL.US) With Buy Rating, Raises Target Price to $12 - Moomoo
RCEL | Avita Medical, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
AVITA Medical (RCEL) Stock Fair Value Rises After PermeaDerm Data And Analyst Target Increases - Yahoo Finance
AVITA Medical: Favorable Reimbursements For Skin Wound Care (NASDAQ:RCEL) - Seeking Alpha
Avita Medical (RCEL) Stock Forum and Discussion - Moomoo
RCEL Maintained by TD Cowen -- Price Target Raised to $14.00 - GuruFocus
TD Cowen raises Avita Medical stock price target on PermeaDerm data - Investing.com Canada
RCEL Maintained by BTIG -- Price Target Raised to $11.00 - GuruFocus
AVITA Medical (NASDAQ:RCEL) Raises Full-Year Guidance on Spray-On Skin Adoption - Kalkine Media
Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
BTIG raises Avita Medical stock price target on positive trial data - Investing.com Canada
TD Cowen Maintains Avita Medical(RCEL.US) With Buy Rating, Raises Target Price to $14 - Moomoo
AVITA Medical Reveals PermeaDerm Trial Results: 70% Cost Reduction Compared to Allograft - Kalkine Media
Avita Medical Inc. (NASDAQ:RCEL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
AVITA Medical (ASX:AVH) Jumps 23.18% as Shares Extend a 67% One-Year Recovery - Kalkine
AVITA Medical (ASX:AVH) Soars 22.73% as Revenue Upgrade and Cash-Flow Target Reset the Conversation - Kalkine
AVITA Medical (ASX: AVH) Reports 70% Cost Advantage for PermeaDerm in Randomized Study - Kalkine
Avita Medical Says Clinical Study for Biosynthetic Wound Matrix Meets Primary Endpoint - marketscreener.com
AVITA Medical's PermeaDerm-I Study Reveals 70% Cost Savings Over Cadaveric Allograft with Equivalent Clinical Results - Kalkine Media
AVITA Medical Inc to Host Key Opinion Leader Webinar Transcript - GuruFocus
AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes - Investing News Network
RCEL Looks 21.8% Undervalued on GF Value™ - GuruFocus
Avita Medical Says PermeaDerm Study Meets Primary Endpoint, Showing 70% Cost Reduction - marketscreener.com
AVITA Medical’s PermeaDerm shows 70% cost savings over allograft By Investing.com - Investing.com Canada
A wound matrix cut prep time 96% with outcomes comparable to cadaver grafts - Stock Titan
Avita Medical Raises Full Year 2026 Revenue Guidance - sekbernews.id
Avita Medical Raises Revenue Guidance and Targets Breakeven - sekbernews.id
AVITA Medical Inc Annual Shareholders Meeting Transcript - GuruFocus
RCEL Q2 2026 Earnings: Narrower Quarterly Loss Beats Estimates; Shares Slip 2%Earnings Quality Analysis - Vinanet
AVITA Medical, Inc. (RCEL) Shareholder/Analyst CallSlideshow (NASDAQ:RCEL) 2026-08-16 - Seeking Alpha
Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18% - MarketBeat
Avita Medical Targets Q4 2025 Cash Flow Breakeven as Revenue Growth Builds - MarketBeat
RCEL Q2 2026 Earnings: EPS Beat of 14.5% Overshadowed by a 2% Stock DeclineEarnings Expansion Phase - Vinanet
RCEL Q2 2026 Earnings: Loss Narrower Than Expected, Delivering 14.5% EPS SurpriseSpecial Dividend Alert - Vinanet
RCEL Q2 2026 Earnings: Narrower Loss Beats Expectations as Shares Edge LowerEstimate Revision Count - Vinanet
AVITA Medical Inc (RCEL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
AVITA Medical (RCEL) Q2 2026 Earnings Call Transcript - AOL.com
Avita Medical (RCEL) Rises 3.57% as Shares Rebound Toward Key ResistanceStock Surge Alerts - vinanet.vn
Avita Medical (RCEL) Dips to $8.12 as Support at $7.71 Moves into FocusPCR Extreme - vinanet.vn
Avita Medical Inc. (ASX:AVH) Share Price Remains Unchanged as Stock Trades Within Daily Range - Kalkine
AVITA Medical at canaccord growth conference: growth resumes By Investing.com - Investing.com Canada
AVITA Medical Inc (ASX:AVH) Shares Reach 52-Week High at AUD 2.30 - Kalkine
Avita Medical Issues 7,260 Restricted US Stock Units to Key Management Personnel - Kalkine
Form 8K Avita Medical Ltd For: 11 August By Investing.com - Investing.com Nigeria
Avita Medical amends agreement with Stedical Scientific to expand distribution rights - Investing.com Nigeria
Avita Medical Inc. (ASX:AVH) Share Market Overview and Biotechnology Sector Profile - Kalkine
Avita Medical Target Price Raised 52% to A$1.90/Share by Canaccord Genuity>AVH.AU - Moomoo
Avita Medical Company Profile & Introduction - Moomoo
AVITA Medical to Host Investor Webinar Briefing on 12 August 2026 - Kalkine
0.86%
0.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):